Haemonetics Stock Price, News & Analysis (NYSE:HAE)

$63.94 -0.18 (-0.28 %)
(As of 01/17/2018 01:55 AM ET)
Previous Close$64.12
Today's Range$63.36 - $64.77
52-Week Range$36.44 - $64.99
Volume358,300 shs
Average Volume537,520 shs
Market Capitalization$3.39 billion
P/E Ratio799.35
Dividend YieldN/A
Beta0.99

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100

Debt

Debt-to-Equity Ratio0.22%
Current Ratio2.17%
Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio799.349918739842
Forward P/E Ratio37.83
P/E Growth4.84

Sales & Book Value

Annual Sales$886.12 million
Price / Sales3.81
Cash Flow$3.24 per share
Price / Cash19.73
Book Value$14.22 per share
Price / Book4.50

Profitability

Trailing EPS$0.08
Net Income$-26,260,000.00
Net Margins0.50%
Return on Equity11.16%
Return on Assets6.79%

Miscellaneous

Employees3,107
Outstanding Shares52,820,000

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How were Haemonetics' earnings last quarter?

Haemonetics Corporation (NYSE:HAE) issued its earnings results on Tuesday, November, 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.07. The medical instruments supplier had revenue of $225.40 million for the quarter, compared to analysts' expectations of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The company's revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.38 earnings per share. View Haemonetics' Earnings History.

When will Haemonetics make its next earnings announcement?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY18 earnings guidance on Tuesday, November, 7th. The company provided EPS guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.61. The company issued revenue guidance of to approximate FY17 of $886.1 million, compared to the consensus revenue estimate of $889.45 million.

Where is Haemonetics' stock going? Where will Haemonetics' stock price be in 2018?

6 brokerages have issued twelve-month target prices for Haemonetics' stock. Their predictions range from $50.00 to $75.00. On average, they anticipate Haemonetics' share price to reach $56.60 in the next year. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:

  • Christopher Simon, President, Chief Executive Officer, Director (Age 53)
  • William P. Burke, Chief Financial Officer, Executive Vice President (Age 49)
  • David J. Wilson, President - Plasma Business Unit
  • Michelle Basil, Executive Vice President, General Counsel (Age 45)
  • Neil Ryding, Executive Vice President, Global Operations (Age 56)
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board (Age 68)
  • Robert E. Abernathy, Director (Age 62)
  • Catherine M. Burzik, Independent Director (Age 67)
  • Charles J. Dockendorff, Independent Director (Age 62)
  • Susan Bartlett Foote, Independent Director (Age 70)

Who owns Haemonetics stock?

Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.04%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Mark W Kroll, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

Who bought Haemonetics stock? Who is buying Haemonetics stock?

Haemonetics' stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Haemonetics.

How do I buy Haemonetics stock?

Shares of Haemonetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of Haemonetics stock can currently be purchased for approximately $63.94.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $3.39 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Haemonetics (NYSE:HAE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.602.502.13
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.60$51.20$44.60$37.86
Price Target Upside: 9.73% downside5.60% downside3.84% downside3.74% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Jefferies GroupBoost Price TargetTop Pick -> Buy$18.00 -> $75.00LowView Rating Details
1/2/2018Raymond James FinancialUpgradeUnderperform -> Market PerformHighView Rating Details
1/2/2018Morgan StanleyUpgradeEqual Weight -> Overweight$51.00HighView Rating Details
11/8/2017Craig HallumReiterated RatingHold$40.00 -> $50.00N/AView Rating Details
11/8/2017Barrington ResearchBoost Price TargetOutperform$48.00 -> $57.00N/AView Rating Details
7/13/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$50.00HighView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016BenchmarkBoost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs GroupUpgradeSell -> Neutral$29.00N/AView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018$0.44N/AView Earnings Details
11/7/2017Q2 2018$0.41$0.48$219.12 million$225.40 millionViewN/AView Earnings Details
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
11/1/2010Q2 2011$0.38$0.40ViewN/AView Earnings Details
8/2/2010Q1 2011$0.36$0.37ViewN/AView Earnings Details
5/4/2010Q4 2010$0.38$0.38ViewN/AView Earnings Details
2/1/2010Q3 2010$0.36$0.35ViewN/AView Earnings Details
11/2/2009Q2 2010$0.33$0.34ViewN/AView Earnings Details
8/3/2009Q1 2010$0.33$0.35ViewN/AView Earnings Details
5/4/2009Q4 2009$0.32$0.32ViewN/AView Earnings Details
2/2/2009Q3 2009$0.31$0.32ViewN/AView Earnings Details
10/27/2008Q2 2009$0.28$0.29ViewN/AView Earnings Details
8/1/2008Q1 2009$0.28$0.29ViewN/AView Earnings Details
5/1/2008Q4 2008$0.29$0.29ViewN/AView Earnings Details
1/31/2008Q3 2008$0.27$0.29ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Haemonetics (NYSE:HAE) Earnings Estimates

2018 EPS Consensus Estimate: $1.59
2019 EPS Consensus Estimate: $1.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.41$0.45$0.43
Q4 20182$0.40$0.45$0.43
Q1 20191$0.41$0.41$0.41
Q2 20191$0.46$0.46$0.46
Q3 20191$0.46$0.46$0.46
Q4 20191$0.43$0.43$0.43
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics (NYSE:HAE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Mark W KrollDirectorSell7,118$63.00$448,434.0033,881View SEC Filing  
12/1/2017Pedro P GranadilloDirectorSell7,118$57.06$406,153.0831,663View SEC Filing  
11/16/2017Ronald G GelbmanDirectorSell5,440$56.69$308,393.60View SEC Filing  
11/14/2017Willaim P BurkeCFOSell13,193$54.04$712,949.7227,227View SEC Filing  
11/13/2017Dan GoldsteinCAOSell4,691$54.93$257,676.633,747View SEC Filing  
11/10/2017Susan Bartlett FooteDirectorSell16,926$54.19$917,219.9427,313View SEC Filing  
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.4324,925View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.9049,688View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.1822,088View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.7212,010View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.6845,350View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.1420,096View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.6120,464View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35147,040View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95147,040View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.9838,188View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.449,939View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.1814,901View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00130,307View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.0028,950View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.2614,901View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00130,307View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.0039,173View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00130,307View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.0016,905View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.8025,166View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00130,307View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.2216,905View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.0016,905View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00130,307View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.0016,905View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.6616,905View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00130,307View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.0010,987View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.0011,337View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.0011,337View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00115,798View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Haemonetics (NYSE HAE) News Headlines

Source:
DateHeadline
Technical Perspectives on Medical Supplies Stocks -- DENTSPLY SIRONA, Baxter, Haemonetics, and Hill-RomTechnical Perspectives on Medical Supplies Stocks -- DENTSPLY SIRONA, Baxter, Haemonetics, and Hill-Rom
www.prnewswire.com - January 16 at 6:24 AM
$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter
www.americanbankingnews.com - January 15 at 9:04 AM
Haemonetics (HAE) Cut to Hold at Zacks Investment ResearchHaemonetics (HAE) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 3:52 PM
Haemonetics Corporation (HAE) to Post Q3 2018 Earnings of $0.45 Per Share, Jefferies Group ForecastsHaemonetics Corporation (HAE) to Post Q3 2018 Earnings of $0.45 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 10 at 12:38 PM
Haemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group ForecastsHaemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 9 at 11:56 PM
Haemonetics (HAE) Rating Increased to Buy at Zacks Investment ResearchHaemonetics (HAE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 9 at 3:56 PM
HAE Crosses Above Average Analyst TargetHAE Crosses Above Average Analyst Target
www.nasdaq.com - January 8 at 3:26 PM
Haemonetics (HAE) PT Raised to $75.00 at Jefferies GroupHaemonetics (HAE) PT Raised to $75.00 at Jefferies Group
www.americanbankingnews.com - January 8 at 8:02 AM
Mark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) StockMark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock
www.americanbankingnews.com - January 3 at 9:28 PM
Haemonetics Corp. (HAE) Has Broken Out To A New High For The YearHaemonetics Corp. (HAE) Has Broken Out To A New High For The Year
www.nasdaq.com - January 2 at 3:25 PM
Morgan Stanley Turns Bullish On Haemonetics, Raymond James Moves To The SidelinesMorgan Stanley Turns Bullish On Haemonetics, Raymond James Moves To The Sidelines
www.msn.com - January 2 at 3:25 PM
Haemonetics (HAE) Upgraded at Raymond James FinancialHaemonetics (HAE) Upgraded at Raymond James Financial
www.americanbankingnews.com - January 2 at 11:04 AM
Haemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from BrokeragesHaemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 1:32 AM
Haemonetics Corp. :HAE-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018Haemonetics Corp. :HAE-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:22 PM
Zacks: Analysts Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.94 MillionZacks: Analysts Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.94 Million
www.americanbankingnews.com - December 31 at 5:00 AM
Haemonetics Corporation (HAE) Expected to Post Earnings of $0.44 Per ShareHaemonetics Corporation (HAE) Expected to Post Earnings of $0.44 Per Share
www.americanbankingnews.com - December 29 at 3:22 PM
Haemonetics Sets Date for Publishing Third Quarter Fiscal 2018 Results: February 6, 2018Haemonetics Sets Date for Publishing Third Quarter Fiscal 2018 Results: February 6, 2018
finance.yahoo.com - December 22 at 8:39 PM
Free Research Report as Haemonetics’s Revenue Grew 2.3%; Adjusted EPS Surged 4.3%Free Research Report as Haemonetics’s Revenue Grew 2.3%; Adjusted EPS Surged 4.3%
finance.yahoo.com - December 22 at 3:38 PM
Zacks: Analysts Expect Haemonetics Corporation (HAE) Will Post Quarterly Sales of $226.94 MillionZacks: Analysts Expect Haemonetics Corporation (HAE) Will Post Quarterly Sales of $226.94 Million
www.americanbankingnews.com - December 14 at 2:54 PM
Haemonetics Corporation (HAE) Given Consensus Rating of "Hold" by AnalystsHaemonetics Corporation (HAE) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 8 at 1:52 AM
Haemonetics Corporation (HAE) Director Pedro P. Granadillo Sells 7,118 SharesHaemonetics Corporation (HAE) Director Pedro P. Granadillo Sells 7,118 Shares
www.americanbankingnews.com - December 4 at 6:12 PM
$226.94 Million in Sales Expected for Haemonetics Corporation (HAE) This Quarter$226.94 Million in Sales Expected for Haemonetics Corporation (HAE) This Quarter
www.americanbankingnews.com - November 26 at 10:08 AM
Haemonetics (HAE) at 52-Week High: Whats Driving the Stock?Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
www.zacks.com - November 20 at 7:51 PM
Zacks Investment Research Lowers Haemonetics Corporation (HAE) to HoldZacks Investment Research Lowers Haemonetics Corporation (HAE) to Hold
www.americanbankingnews.com - November 20 at 1:32 PM
Insider Selling: Haemonetics Co. (HAE) Director Sells 5,440 Shares of StockInsider Selling: Haemonetics Co. (HAE) Director Sells 5,440 Shares of Stock
www.americanbankingnews.com - November 17 at 8:37 PM
Zacks Investment Research Upgrades Haemonetics Corporation (HAE) to "Buy"Zacks Investment Research Upgrades Haemonetics Corporation (HAE) to "Buy"
www.americanbankingnews.com - November 17 at 1:54 PM
Haemonetics Co. (HAE) CFO Willaim P. Burke Sells 13,193 SharesHaemonetics Co. (HAE) CFO Willaim P. Burke Sells 13,193 Shares
www.americanbankingnews.com - November 16 at 8:12 PM
Haemonetics Corporation (HAE) CAO Dan Goldstein Sells 4,691 SharesHaemonetics Corporation (HAE) CAO Dan Goldstein Sells 4,691 Shares
www.americanbankingnews.com - November 15 at 8:44 PM
Haemonetics Corporation (HAE) Director Susan Bartlett Foote Sells 16,926 SharesHaemonetics Corporation (HAE) Director Susan Bartlett Foote Sells 16,926 Shares
www.americanbankingnews.com - November 14 at 8:04 PM
Haemonetics Corporation (HAE) Receives Consensus Recommendation of "Hold" from AnalystsHaemonetics Corporation (HAE) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 2:34 AM
Haemonetics Shows Market Leadership With Jump To 91 RS RatingHaemonetics Shows Market Leadership With Jump To 91 RS Rating
finance.yahoo.com - November 11 at 5:35 AM
Jefferies Group Weighs in on Haemonetics Corporations Q3 2018 Earnings (HAE)Jefferies Group Weighs in on Haemonetics Corporation's Q3 2018 Earnings (HAE)
www.americanbankingnews.com - November 10 at 4:20 PM
Q3 2018 Earnings Estimate for Haemonetics Corporation Issued By Barrington Research (HAE)Q3 2018 Earnings Estimate for Haemonetics Corporation Issued By Barrington Research (HAE)
www.americanbankingnews.com - November 10 at 4:20 PM
Research Analysts Issue Forecasts for Haemonetics Corporations FY2018 Earnings (HAE)Research Analysts Issue Forecasts for Haemonetics Corporation's FY2018 Earnings (HAE)
www.americanbankingnews.com - November 9 at 2:24 PM
FY2018 Earnings Forecast for Haemonetics Corporation (HAE) Issued By William BlairFY2018 Earnings Forecast for Haemonetics Corporation (HAE) Issued By William Blair
www.americanbankingnews.com - November 9 at 2:24 PM
Haemonetics (HAE) in Focus: Stock Moves 10% HigherHaemonetics (HAE) in Focus: Stock Moves 10% Higher
www.zacks.com - November 9 at 6:28 AM
Craig Hallum Reaffirms "Hold" Rating for Haemonetics Corporation (HAE)Craig Hallum Reaffirms "Hold" Rating for Haemonetics Corporation (HAE)
www.americanbankingnews.com - November 8 at 4:30 PM
Haemonetics Corp. (HAE) Leaped To A New High On Strong Q2 EarningsHaemonetics Corp. (HAE) Leaped To A New High On Strong Q2 Earnings
www.rttnews.com - November 8 at 8:49 AM
Haemonetics Corp. (HAE) Leaped To A New High On Strong Q2 EarningsHaemonetics Corp. (HAE) Leaped To A New High On Strong Q2 Earnings
www.rttnews.com - November 8 at 8:49 AM
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View UpHaemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
www.zacks.com - November 8 at 8:49 AM
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View UpHaemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
www.zacks.com - November 8 at 8:49 AM
Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 2nd Quarter and 1st Half Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics tops Street 2Q forecastsHaemonetics tops Street 2Q forecasts
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics tops Street 2Q forecastsHaemonetics tops Street 2Q forecasts
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics announces plans to cut 350 jobsHaemonetics announces plans to cut 350 jobs
finance.yahoo.com - November 8 at 8:49 AM
Haemonetics announces plans to cut 350 jobsHaemonetics announces plans to cut 350 jobs
finance.yahoo.com - November 8 at 8:49 AM
ETFs with exposure to Haemonetics Corp. : November 7, 2017ETFs with exposure to Haemonetics Corp. : November 7, 2017
finance.yahoo.com - November 8 at 8:49 AM
ETFs with exposure to Haemonetics Corp. : November 7, 2017ETFs with exposure to Haemonetics Corp. : November 7, 2017
finance.yahoo.com - November 8 at 8:49 AM
Edited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of HAE earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 8:49 AM

SEC Filings

Haemonetics (NYSE:HAE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Haemonetics (NYSE HAE) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.